Comparative Pharmacology
Head-to-head clinical analysis: HYDRO RIDE versus HYDRO RX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO RIDE versus HYDRO RX.
HYDRO-RIDE vs HYDRO-RX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis, decreased plasma volume, and vasodilation. It also reduces peripheral vascular resistance.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
Initial: 25 mg orally once daily; may increase to 50 mg once daily after 2 weeks based on response. Maximum: 50 mg daily.
None Documented
None Documented
Terminal half-life 4-6 hours (prolonged in renal impairment).
Terminal elimination half-life is 8-12 hours in adults with normal renal function; extended to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Renal excretion of unchanged drug accounts for 60% of elimination; biliary/fecal excretion accounts for 30%; 10% metabolized.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic